News & Commentary

As many 2023 state legislative sessions come to an end, it is a good time to take a closer look at two states—one in the South and one in the Northeast—to see how they are tackling some of the most pressing matters impacting 340B stakeholders. … [Read more...]

As we reach the third-year mark since pharmaceutical manufacturers began to restrict access to 340B pricing in the contract pharmacy setting, we recently experienced a watershed moment that I believe will lead to an end of the standoff between the … [Read more...]

With the recent launch of 340B Truth and with several other advocacy/educational groups using 340B in their names, it is a good time to provide a tutorial on the different groups and their goals.  The list below is not exhaustive but reflects … [Read more...]

Many of us in the 340B community are still trying to digest the news that the National Association of Community Health Centers has formed an alliance with PhRMA and will be advocating for major reforms to the 340B program. … [Read more...]

For the past three decades, hospitals and federal grantees have been more successful than pharmaceutical companies when it comes to policy changes to the 340B drug discount program.  Despite the drug industry’s deeper pockets, 340B covered entities … [Read more...]

I am very excited to be writing my inaugural column for Verity Solutions’ blog.  I have a long-time friendship with Verity’s CEO George Puckett that spans close to three decades and have always admired and counted on the Verity team for their … [Read more...]

Political pundits and others in Washington, D.C. should be thankful that betting on U.S. elections is illegal. Otherwise, there would have been a lot of money lost on the Congressional midterm races where the expected “red wave” never materialized. … [Read more...]

As we approach the 340B drug discount program's 30th anniversary on November 4, it is a good time to reflect on the key moments that have had the greatest impact on this very important program. I have been immersed in the program since 1996, but … [Read more...]

October will be critical in the ongoing dispute over the scope of the 340B contract pharmacy program. The U.S. Court of Appeals for the District of Columbia Circuit has scheduled oral arguments on Oct. 24 in Novartis and United Therapeutics’ … [Read more...]

Significant health care policy change occurs very infrequently in Washington, D.C. This is particularly the case with drug pricing, where advocates have been fighting for more than 30 years over letting Medicare negotiate pharmaceutical prices. … [Read more...]